Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management

被引：19

作者：

Girmenia, Corrado ^{[1
]}

Busca, Alessandro ^{[2
]}

Candoni, Anna ^{[3
]}

Cesaro, Simone ^{[4
]}

Luppi, Mario ^{[5
]}

Nosari, Anna Maria ^{[6
,7
]}

Pagano, Livio ^{[8
]}

Rossi, Giuseppe ^{[9
,10
]}

Venditti, Adriano ^{[11
]}

Aversa, Franco ^{[12
]}

机构：

[1] Azienda Policlin Umberto I, Dipartimento Ematol Oncol & Dermatol, Via Benevento, I-00161 Rome, Italy

[2] AOU Citta Salute & Sci, Dipartimento Oncol, SSD Trapianto Allogen Cellule Staminali, Turin, Italy

[3] Azienda Osped Univ Udine, Ctr Trapianti & Terapie Cellulari, Clin Ematol, Udine, Italy

[4] Azienda Osped Univ Integrata, Oncoematol Pediat, Verona, Italy

[5] UNIMORE, AOU Modena, Cattedra & UO Ematol, Dipartimento Sci Med & Chirurg Materno Infantile, Modena, Italy

[6] ASST Grande Osped Metropolitano Niguarda, Div Ematol, Milan, Italy

[7] ASST Grande Osped Metropolitano Niguarda, Ctr Trapianti Midollo, Milan, Italy

[8] Univ Cattolica Sacro Cuore, IRCCS, Fdn Policlin A Gemelli, Div Ematol, Rome, Italy

[9] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[10] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[11] Fdn Policlin Tor Vergata, Ematol, Rome, Italy

[12] Univ Parma, Haematol & BMT Unit, Parma, Italy

来源：

MEDICAL MYCOLOGY | 2019年 / 57卷

关键词：

breakthrough fungal infections; antifungal prophylaxis; acute myeloid leukemia; triazoles; PRIMARY ANTIFUNGAL PROPHYLAXIS; ACUTE MYELOGENOUS LEUKEMIA; POSACONAZOLE PROPHYLAXIS; T-CELLS; CLINICAL EFFECTIVENESS; NEUTROPENIC PATIENTS; HEMATOLOGY PATIENTS; MYELODYSPLASTIC SYNDROMES; CYTOTOXIC CHEMOTHERAPY; INDUCTION CHEMOTHERAPY;

D O I：

10.1093/mmy/myy091

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."

引用

页码：S127 / S137

页数：11

共 66 条

[1] Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period
Ananda-Rajah, Michelle R.
Grigg, Andrew
Downey, Maria T.
Bajel, Ashish
Spelman, Tim
Cheng, Allen
Thursky, Karin T.
Vincent, Janette
Slavin, Monica A.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03): : 459 - 463
[2] Arikan-Akdagli S, 2012, ANN NY ACAD SCI, V1272, P14
[3] Galactomannan and Polymerase Chain Reaction-Based Screening for Invasive Aspergillosis Among High-Risk Hematology Patients: A Diagnostic Meta-analysis
Arvanitis, Marios
Anagnostou, Theodora
Mylonakis, Eleftherios
[J]. CLINICAL INFECTIOUS DISEASES, 2015, 61 (08) : 1263 - 1272
[4] Fungus-Specific CD4+ T Cells for Rapid Identification of Invasive Pulmonary Mold Infection
Bacher, Petra
Steinbach, Angela
Kniemeyer, Olaf
Hamprecht, Axel
Assenmacher, Mario
Vehreschild, Maria J. G. T.
Vehreschild, Joerg J.
Brakhage, Axel A.
Cornely, Oliver A.
Scheffold, Alexander
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (03) : 348 - 352
[5] The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole
Barreto, Jason N.
Beach, Cassidy L.
Wolf, Robert C.
Merten, Julianna A.
Tosh, Pritish K.
Wilson, John W.
Hogan, William J.
Litzow, Mark R.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (04) : 283 - 288
[6] Belling Morgan, 2017, Leuk Res Treatment, V2017, P3460892, DOI 10.1155/2017/3460892
[7] Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting
Berking, Sophie
Doedens, Daphne
Horns, Heidi
Fiegl, Michael
Ostermann, Helmut
Rieger, Christina T.
[J]. MYCOSES, 2017, 60 (09) : 600 - 606
[8] A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis
Biehl, Lena M.
Vehreschild, J. Janne
Liss, Blasius
Franke, Bernd
Markiefka, Birgid
Persigehl, Thorsten
Buecker, Vanessa
Wisplinghoff, Hilmar
Scheid, Christof
Cornely, Oliver A.
Vehreschild, Maria J. G. T.
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (09) : 2634 - 2641
[9] Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections
Cattaneo, Chiara
Panzali, Annafranca
Passi, Angela
Borlenghi, Erika
Lamorgese, Cinzia
Petulla, Marta
Re, Alessandro
Caimi, Luigi
Rossi, Giuseppe
[J]. MYCOSES, 2015, 58 (06) : 362 - 367
[10] Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations
Cho, Sung-Yeon
Lee, Dong-Gun
Choi, Su-Mi
Choi, Jae-Ki
Lee, Hyo-Jin
Kim, Si-Hyun
Park, Sun Hee
Choi, Jung-Hyun
Yoo, Jin-Hong
Kim, Yoo-Jin
Kim, Hee-Je
Min, Woo-Sung
[J]. MYCOSES, 2015, 58 (09) : 565 - 571

← 1 2 3 4 5 6 7 →